GlobeNewswire: Boston Therapeutics, Inc. Contains the last 10 of 123 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T18:56:48ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/08/22/1905677/0/en/Boston-Therapeutics-Ph-2-Study-Achieves-Full-Enrollment.html?f=22&fvtc=4&fvtv=35067Boston Therapeutics Ph 2 Study Achieves Full Enrollment2019-08-22T17:55:07Z<![CDATA[Study to evaluate the efficacy and safety of BTI320 in type 2 diabetes patients on metformin and/or sulfonylureas Study to evaluate the efficacy and safety of BTI320 in type 2 diabetes patients on metformin and/or sulfonylureas]]>https://www.globenewswire.com/news-release/2019/02/14/1725666/0/en/Boston-Therapeutics-Announces-Official-Sales-and-Marketing-Launch-of-Sugardown-in-Asia.html?f=22&fvtc=4&fvtv=35067Boston Therapeutics Announces Official Sales and Marketing Launch of Sugardown® in Asia2019-02-14T16:18:01Z<![CDATA[LAWRENCE, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “Company” or “BTI”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel therapeutics as an adjunct therapy for diabetes, launches the initial sales and marketing of cross border products in China via one of the largest e-commerce platform: Tao Bao. Newly manufactured Sugardown® chewable tablets have been received in China in Jan 2019 to support the launching of product by an elite e-marketing group (JD Jin Long) in China. The campaign, which features a series of promotional offers, will be the e-focus to drive sales for the next four weeks. A total of 5,000 units have been allocated for this initial sales launch. Taking advantage of this expensive social commerce infrastructure that is unique to Asia, we intend to expand our territories with initial efforts in the Shandong province.]]>https://www.globenewswire.com/news-release/2018/12/13/1666840/0/en/Boston-Therapeutics-Announces-Marketing-of-Sugardown-in-Asia.html?f=22&fvtc=4&fvtv=35067Boston Therapeutics Announces Marketing of Sugardown® in Asia2018-12-13T16:13:52Z<![CDATA[LAWRENCE, Mass., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics, Inc. (the “Company” or “BTI”) (OTCQB: BTHE), an innovator in the design, development and commercialization of novel therapeutics as an adjunct therapy for diabetes, signed a co-marketing agreement with Jin Long Health, a wholly owned subsidiary of China Hiking Group to market Sugardown® chewable tablets in China through Jin Long’s distribution channels including online and dedicated healthcare outlets.]]>https://www.globenewswire.com/news-release/2018/12/07/1663937/0/en/Boston-Therapeutics-Announces-Initiation-of-Sales-of-Sugardown-in-Asia.html?f=22&fvtc=4&fvtv=35067Boston Therapeutics Announces Initiation of Sales of Sugardown® in Asia2018-12-07T18:26:20Z<![CDATA[LAWRENCE, Mass., Dec. 07, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics, Inc. (the “Company” or “BTI”) (OTCQB: BTHE), an innovator in the design, development and commercialization of novel therapeutics as an adjunct therapy for diabetes, launches an initial sale of product in Myanmar and test market in China. Newly manufactured Sugardown® chewable tablets have been received in China and are due for shipment and sale to China Mainland in the next two weeks. The shipment of 6,000 units for Myanmar is planned for release and dispatch in the coming week. This may be a substantial contribution of up to $310,000 to support the Company from its Asian Partner.]]>https://www.globenewswire.com/news-release/2018/10/03/1600712/0/en/Boston-Therapeutics-and-Prevail-InfoWorks-Announce-Strategic-Clinical-Partnership.html?f=22&fvtc=4&fvtv=35067Boston Therapeutics and Prevail InfoWorks Announce Strategic Clinical Partnership2018-10-03T12:15:24Z<![CDATA[Prevail Partners Investing up to $500,000 in Boston Therapeutics Prevail Partners Investing up to $500,000 in Boston Therapeutics]]>https://www.globenewswire.com/news-release/2018/09/24/1575156/0/en/Boston-Therapeutics-Initiates-New-Exploratory-and-Adaptive-Multicenter-Clinical-Study-of-BTI320-On-Type-2-Diabetics-Currently-on-Metformin-and-or-Sulfonylureas-in-the-United-States.html?f=22&fvtc=4&fvtv=35067Boston Therapeutics Initiates New Exploratory and Adaptive Multicenter Clinical Study of BTI320 On Type 2 Diabetics Currently on Metformin and or Sulfonylureas in the United States2018-09-24T15:35:15Z<![CDATA[LAWRENCE, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “Company” or “BTI”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel therapeutics as an adjunct therapy for diabetes, announces the start of a new double-blind, placebo-controlled study that will confirm the potential of the newly patented (EU) investigative material to support and possibly enhance current anti-diabetic regimen of glycemic control in subjects with type diabetes. First subject in the multicenter trial was consented on September 18, 2018. The objective of this confirmatory, proof of concept adaptive study is to assess appropriate efficacy of clinical benefit and contribute to the growing safety of BTI320. This will be compared to placebo and will also have the addition of metformin and/or sulfonylureas on critical glycemic control over a 12-week duration in a diseased population. BTI320 has been shown to significantly decrease postprandial glucose excursions, a key immediate impactful influence on red cell protein glycation which then persists for months (BMC Endocrine Disorders, https://bmcendocrdisord.biomedcentral.com/track/pdf/10.1186/s12902-018-0288-5). It is hypothesized that BTI320, through this simple immediate post-meal effect on blood sugar, may help stall or delay the progression of diabetes and other related complications. BTI320 is designed to reduce glycemic variabilities, as shown by indices captured through the rapidly emerging continuous glucose monitoring systems (CGMS). CGMS is an innovative way to limit “finger sticking “for blood sampling, and replace it with a system that provides reliable immediate understanding of the direct effect of the food and drinks that are being consumed.]]>https://www.globenewswire.com/news-release/2018/08/24/1556462/0/en/Boston-Therapeutics-Phase-IIa-Study-Results-Accepted-for-Publication.html?f=22&fvtc=4&fvtv=35067Boston Therapeutics Phase IIa Study Results Accepted for Publication2018-08-24T13:30:12Z<![CDATA[Primary Proof-of-Concept Study Confirms Post-meal Glucose Attenuation and Weight Reduction in Prediabetes Patients Primary Proof-of-Concept Study Confirms Post-meal Glucose Attenuation and Weight Reduction in Prediabetes Patients]]>https://www.globenewswire.com/news-release/2018/08/09/1549880/0/en/Boston-Therapeutics-to-launch-social-commerce-channel-for-Sugardown-in-China.html?f=22&fvtc=4&fvtv=35067Boston Therapeutics to launch social commerce channel for Sugardown® in China2018-08-09T15:52:28Z<![CDATA[For product distribution via a multi-purpose super-app that fuses communications with commerce For product distribution via a multi-purpose super-app that fuses communications with commerce]]>60 Tablet BottleSugardown®Healthy ChoicesSugardown®Chewable TabletSugardown®Purchase OnlineSugardown®https://www.globenewswire.com/news-release/2018/06/27/1530535/0/en/Boston-Therapeutics-Introduces-Sugardown-to-the-US-under-kathy-Ireland-Health-Wellness.html?f=22&fvtc=4&fvtv=35067Boston Therapeutics Introduces Sugardown® to the US under kathy Ireland® Health & Wellness2018-06-27T16:52:50Z<![CDATA[LAWRENCE, Mass., June 27, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “Company” or “BTI”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel therapeutics for metabolism and sugar control for conditions such as pre-diabetes, diabetes and related complications, announces new promotional and educational partner for health and wellness branding and marketing of its new dietary supplement, Sugardown®. Licensed in an agreement between Boston Therapeutics and Level Brands, Inc. (NYSE American:LEVB), the kathy Ireland® Health & Wellness brand can set the stage for the broad commercialization of Sugardown®.]]>https://www.globenewswire.com/news-release/2018/05/22/1510312/0/en/Boston-Therapeutics-Initiates-New-Clinical-Study-of-BTI-320.html?f=22&fvtc=4&fvtv=35067Boston Therapeutics Initiates New Clinical Study of BTI-3202018-05-22T16:58:44Z<![CDATA[Supported by Grant from Innovation and Technology Commission in Hong Kong Supported by Grant from Innovation and Technology Commission in Hong Kong]]>